RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.
Chapman MA, et al. Among authors: braganza n.
Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.
Blood. 2018.
PMID: 30181174
Free PMC article.
Clinical Trial.